Self-titration of inhaled corticosteroid and beta2-agonist in response to symptoms in mild asthma - a pre-specified analysis from the PRACTICAL study, a randomised controlled trial - Articles - Pneumology

RECOMMENDED

Asthma

Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma - findings from the PRACTICAL study, a randomised clinical trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir J.

Baggott C, Reddel HK, Hardy J, Sparks J, Holliday M, Corin A, Montgomery B, Reid J, Sheahan D, Hancox RJ, Weatherall M, Beasley R, Fingleton J, PRACTICAL study team.

doi: 10.1183/13993003.02073-2019.

COMMENTED

Asthma

Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

Lancet Respir Med.

Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Mansur AH, Fowler SJ, Niven RM, Howarth PH, Lordan JL, Menzies-Gow A, Harrison TW, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, investigators for the MRC Refractory Asthma Stratification Programme.

doi: 10.1016/S2213-2600(20)30397-0.

Asthma

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Respir Med.

Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators

doi: 10.1016/

Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial

Lancet Respir Med.

Price DB, Buhl R, Chan A, Freeman D, Gardener E, Godley C, Gruffydd-Jones K, McGarvey L, Ohta K, Ryan D, Syk J, Tan NC, Tan T, Thomas M, Yang S, Konduru PR, Ngantcha M, d'Alcontres MS, Lapperre TS

doi: 10.1016/

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial

Read the comment: Effectiveness trials in asthma: time to SaLSA? >>>

doi: 10.1016/

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines

Horak F, Doberer D, Eber E, Horak E, Pohl W, Riedler J, Szépfalusi Z, Wantke F, Zacharasiewicz A, Studnicka M

COMMENTED

Asthma

Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β₂-agonists for adults with asthma

Respir Med.

Buhl R, FitzGerald JM, Busse WW

doi: 10.1016/j.rmed.2018.08.014.

RECOMMENDED

Asthma

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet.

Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW

doi: 10.1016/S0140-6736(19)32215-9.

RECOMMENDED

Asthma

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Lancet.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R, PRACTICAL study team.

doi: 10.1016/S0140-6736(19)31948-8.

Related content

Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma - findings from the PRACTICAL study, a randomised clinical trial

Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines

Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β₂-agonists for adults with asthma